MENU

Latest News from Arcinova

stdClass Object ( [id] => 302 [title] => C&EN Article: Former drug companies are becoming CROs [alias] => c-en-article-2 [title_alias] => [introtext] =>

Sean Milmo, for Chemical and Engineering News, writes about the growing number of former drug company labs becoming CROs. 

[language] => * [fulltext] =>

Sean Milmo wrote an article in the August edition (Vo. 96, Iss. 32) of C&EN, discussing the evergrowing trend of Europe's drug industry, looking to increase efficiency and in turn cut costs, raise productivity and focus on more profitable theraputics areas. 

Sean acknowledges that "whole research units are being closed or transferred to new owners that want to economize with fewer employees, but researchers have a reasonable prospect of finding work in an R&D sector that is no longer dominated by pharmaceutical multinationals."

Speaking to Ian Shott on Arcinova, a site which was acquired from Covance in 2016, "we changed the whole business and made 62 people redundant out of a total staff of 112 in the first month,” Shott recalls. “We have since hired 50 scientists and over the next three to four years plan to recruit another 200.”

To download the full article, please click on the link below.

Click here to visit website

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-08-07 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-08-08 08:50:33 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-08-07 16:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/CEN News Article.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/API 20L SQuare.png","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => Alex Scott, Senior Editor for Europe of Chemical and Engineering News, writes about Ian Shott's acquisition of the Alnwick site and prospects going forward. [access] => 1 [hits] => 35 [xreference] => [featured] => 0 [readmore] => 1106 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-08-07 11:06:00 [slug] => 302:c-en-article-2 [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Sean Milmo, for Chemical and Engineering News, writes about the growing number of former drug company labs becoming CROs. 

)

C&EN Article: Former drug companies are becoming CROs

Sean Milmo wrote an article in the August edition (Vo. 96, Iss. 32) of C&EN, discussing the evergrowing trend of Europe's drug industry, looking ...

Find Out More

stdClass Object ( [id] => 299 [title] => How prepared is UK manufacturing for Brexit? [alias] => how-prepared-is-the-uk-to-leave-the-eu [title_alias] => [introtext] =>

With six months to go until we leave the EU, how prepared is UK manufacturing for Brexit? 

[language] => * [fulltext] =>

With six months to go until we leave the EU, how prepared is UK manufacturing for Brexit? Ian Shott, Executive Chairman and CEO of Arcinova shares his thoughts on UK manufacturing in preparation for Brexit. 

For decades we’ve been reliant on Europe for imports of certain goods. With Brexit on the horizon, ministers are looking at how we can make a change and start to replace that with local manufacturing on UK soil. 

From the conversations I’ve been having with ministers it’s clear they see Brexit as a golden opportunity to stimulate what we do here in the UK and they’re highly motivated to support a reindustrialisation of the country supported by the Industrial Strategy, increased Government funding for Science and Innovation and a number of fiscal levers such as R&D tax credits, lower SME corporation tax and Entrepreneurs relief. 

There are fears that new import and export rules could cripple manufacturing firms. We’ve been so used to a frictionless movement of products across borders that the thought of having to battle our way through red tape is unsettling. 

As a CEO I’m cautiously optimistic because in the private sector our natural instinct is to accept the reality of the situation and work out how to manage it. I believe that this is what we’ll do collectively.

Recent news shows a strong commitment from the Prime Minister to find a win-win solution that preserves frictionless trade with the EU. What matters now is that both sides do a deal that’s sensible and I remain confident that common sense will prevail. Brexit will consume more airtime than it should but I also believe that businesses will focus on the opportunities that present themselves from whatever is the outcome and change always generates opportunity, often unexpected.

 

 

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-07-13 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-07-23 15:24:06 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-07-13 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/website SQuare - EU Map 2.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/Website Portraits - Ian shott 2.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 173 [xreference] => [featured] => 0 [readmore] => 1888 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-07-13 11:06:00 [slug] => 299:how-prepared-is-the-uk-to-leave-the-eu [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

With six months to go until we leave the EU, how prepared is UK manufacturing for Brexit? 

)

How prepared is UK manufacturing for Brexit?

With six months to go until we leave the EU, how prepared is UK manufacturing for Brexit? Ian Shott, Executive Chairman and CEO of ...

Find Out More

stdClass Object ( [id] => 221 [title] => Two new recruits join our Isotope Labelling team [alias] => arcinova-strengthens-isotope-labelling-department-with-new [title_alias] => [introtext] =>

We have boosted our Isotope Labelling department with the addition of two new PhD chemists. 

[language] => * [fulltext] =>

Andrew Watson has joined Arcinova’s Isotope Labelling team as a Radiochemist and Zoë Wright has been appointed to the role of Synthetic Chemist. 

Andrew graduated from the University of Leeds with a Master of Chemistry degree and has since completed a PhD in Ruthenium catalysed transformations of alcohols at the University of Bath. He has held a number of post-doctorate research positions with the University of Canterbury, New Zealand, University of Bristol and most recently Cardiff University. 

Zoë has joined Arcinova from The Scripps Research Institute (TSRI) in California where she completed post-doctorate research on novel antiviral treatments for influenza. She has also completed a Master of Chemistry degree at the University of Oxford and holds a PhD in Organic Chemistry and Peptide Synthesis from University College London. 

In their new roles, Zoë and Andrew will focus on synthetic chemistry, where they’ll be responsible for synthesising and radiolabelling Active Pharmaceutical Ingredients (APIs).  

Arcinova’s team are highly experienced in the synthesis and analysis of 14C and stable-labelled compounds. We provide a range of radiolabelling solutions including: custom synthesis of 14C labelled compounds to support pre-clinical ADME studies; GMP synthesis of 14C labelled compounds for human AME studies; handling of 14C labelled gases and volatiles and synthesis of stable-labelled compounds. 

Commenting on his new appointment, Andrew Watson said: “I’m looking forward to utilising my expertise in chemical and radiochemical applications to provide our clients with the best service and consultancy to support their studies from development all the way through to delivery.” 

Zoë added: “It’s an exciting time for me to join the company and I’m looking forward to working with the team and applying my experience in both industrial and academic settings, helping our clients to achieve their objectives.”

Ian Shott, Executive Chairman and CEO of Arcinova, commented: “We are delighted to welcome Zoë and Andrew to the team - they are joining us at a truly exciting time in our development.

“Both Zoë and Andrew have a vast amount of experience which will add further scientific depth to the API department and the wider company as we grow.”

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-07-04 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-07-16 10:52:57 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-07-04 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/website SQuare - IL New starters.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/website SQuare - IL New starters.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 654 [xreference] => [featured] => 0 [readmore] => 2452 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-07-04 11:06:00 [slug] => 221:arcinova-strengthens-isotope-labelling-department-with-new [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

We have boosted our Isotope Labelling department with the addition of two new PhD chemists. 

)

Two new recruits join our Isotope Labelling team

Andrew Watson has joined Arcinova’s Isotope Labelling team as a Radiochemist and Zoë Wright has been appointed to the role of Synthetic Chemist.&...

Find Out More

stdClass Object ( [id] => 294 [title] => New appointments strengthen our Drug Product team [alias] => new-appointments-strengthen-our-drug-product-team [title_alias] => [introtext] => [language] => * [fulltext] =>

We have expanded our Drug Product department with the appointment of Amy Harrison-Potts, Kate Wilson, Louise Armstrong and Alex Jones.

 

The new scientists have been recruited to support the continued expansion of our Drug Product department as international demand for its services grows. 

Amy Harrison, from Sunderland, who graduated from Newcastle University with a degree in Pharmacology in 2016, has joined the team as a Manufacturing Scientist. Her role includes dispensing APIs, drug products and excipients as well as manufacturing packaging for clinical products. 

Northumberland-born and a member of the Royal Society of Chemistry, Kate Wilson has joined Arcinova as an Analytical Scientist, where she will be developing, validating and applying analytical methodologies during quality control and stability evaluation of a range of materials. She completed an integrated master’s degree combining both undergraduate and postgraduate study in Chemistry with Medicinal Chemistry at Newcastle University in 2017. 

Alex Jones, from Gateshead, is a recent graduate from Sunderland University, where he studied Biopharmaceutical Science. He has also joined the team as an Analytical Scientist and his work includes the development, validation and application of analytical methodologies. 

Louise Armstrong, from Widdrington, has taken up the role of a Manufacturing Technician. Louise graduated from Tyneside Metropolitan College, where she obtained a diploma in Pharmaceutical Sciences. As part of her role she supports on the dispensing, manufacture and packaging of clinical products in accordance with GMP requirements.

Commenting on her appointment, Amy Harrison said: “After finishing my degree, I was very keen to enter the pharmaceutical industry.  This role at Arcinova has given me the opportunity to develop my career and enhance my capabilities at a growing North East-based company with a truly global presence.”

Kate Wilson said: “I was attracted to the great variety of work offered by this position at Arcinova – there is the chance to work across numerous projects and it’s an exciting prospect.”

Alex Jones added: “I was very enthusiastic about joining Arcinova, the company is in an exciting growth phase which I wanted to be a part of. I felt that there was an opportunity for me to work with world class scientists and play a role in the development of the CMC department.”    

Louise Armstrong said: “It’s fantastic that there is a company such as Arcinova in North East England, which is providing an opportunity for young scientists to further their careers and work in a welcoming, vibrant environment.”

Ian Shott, executive chairman and managing director of Arcinova, said: “As demand for our drug product services grows, we’re proud to be welcoming talented scientists such as Louise, Kate, Amy and Alex to the team. They have a real passion for their work and are keen to grow with the business as we progress and serve an ever wider segment of the global pharmaceutical and biotech communities. I’m looking forward to seeing them support our Drug Product department and develop their skills here as part of a thriving community of scientists at our Alnwick site.”

 

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-07-04 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-07-09 10:07:03 [modified_by] => 849 [modified_by_name] => tr10.support [publish_up] => 2018-07-04 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/website SQuare - CMC new starters.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/website SQuare - CMC new starters.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 188 [xreference] => [featured] => 0 [readmore] => 3386 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-07-04 11:06:00 [slug] => 294:new-appointments-strengthen-our-drug-product-team [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] => )

New appointments strengthen our Drug Product team

We have expanded our Drug Product department with the appointment of Amy Harrison-Potts, Kate Wilson, Louise Armstrong and Alex Jones.

 

<...

Find Out More

stdClass Object ( [id] => 288 [title] => Senior appointment demonstrates growth ambitions at Arcinova [alias] => senior-appointment-demonstrates-growth-ambitions-at-arcinova [title_alias] => [introtext] =>

Arcinova has appointed a new Chief Scientific Officer to further accelerate the company's growth.

[language] => * [fulltext] =>

An experienced senior business leader, Dr Gareth Jenkins CChem FRSC has joined the Alnwick, UK based firm to support it in applying new technologies which enable the implementation of continuous manufacturing processes.

Arcinova provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies across the globe. It’s offerings include drug substance synthesis, drug product manufacture, Chemistry, Manufacturing and Controls (CMC), bioanalytical and metabolism services, radiolabelling synthesis and synthesis of toxic/highly potent APIs. 

The company also provides consultancy services and works in partnership with companies throughout the drug development process.

Gareth has joined Arcinova from Britest, a manufacturing process consultancy, where he was CEO. His experience includes research, development, scale-up and commercialisation spanning laboratory, kilo-lab, pilot and commercial plant scales. 

In his new role, Gareth will focus on identifying technology that will enable Arcinova to further enhance its innovation-led approach to pharmaceutical development. An initial area of focus will be to drive Arcinova’s adoption of flexible, modular continuous manufacturing processes. In doing so, the organisation and its customers will continue to benefit from streamlined efficiencies in keeping with Arcinova’s agile approach to drug development. Another key element of Gareth’s role will be to harness the power of biology – and in particular the growing field of synthetic biology – to access complex, novel materials from simple, sustainable resources. . 

Prior to joining Arcinova, he was COO, Director and Company Secretary at AM Technology; Process Research & Development Director and Site Quality Manager at AMRI UK; and Vice President Research & Development at Excelsyn Molecular Development. Gareth also holds a PhD and BSc in Chemistry from Imperial College, London and an MBA in Entrepreneurship from Manchester Business School

Commenting on his new appointment, Gareth Jenkins said: “I’m looking forward to supporting the continued expansion of Arcinova. The company has seen impressive growth over the last two years and I feel that I am coming on board at an exciting phase in its development. 

“Arcinova’s commitment to innovation closely aligns with my passion for industrial biotechnology, synthetic biology and continuous manufacturing and process engineering.”

Ian Shott, Executive Chairman and Managing Director of Arcinova, commented: “I first worked with Gareth in 2005 when I was CEO of Excelsyn, a pharmaceutical development and manufacturing services company. I am therefore delighted to be able to welcome Gareth to the Arcinova team – and to be working with him again. 

“Gareth has a wealth of experience in biology and technology and has great ability in identifying areas of a business that can be made more efficient and sourcing the right technology to enable this. I look forward to seeing the impact he will make on Arcinova as we continue our journey and build on our success to date.”

Arcinova recently announced the award of a £1.5 million Innovate UK grant for the development of new flexible modular manufacturing technologies, a project which is set to demonstrate the operating feasibility of world first innovative continuous production tools.

The project, which will span a three-year period, will be undertaken in collaboration with a team at the University of Nottingham. 

Launched in 2016, Arcinova operates from a 15,000m2 facility on a 34-acre site, which has benefited from decades of investment as a key research and development centre for Sanofi and Covance, allowing it to offer a unique range of complementary on-site capabilities as a CRDO.

Arcinova’s senior scientific team are renowned for their world class, specialist research and development expertise and their big pharma and CRDO experience gives them extensive, broad ranging industry knowledge and insight.

Arcinova works with big pharma, specialty pharma and biotech companies across the globe, from established multinationals to emerging start-ups.

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-06-18 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-06-27 11:52:52 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-06-18 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/website SQuare - gareth jenkins.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/website SQuare - gareth jenkins.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 219 [xreference] => [featured] => 0 [readmore] => 4311 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-06-18 11:06:00 [slug] => 288:senior-appointment-demonstrates-growth-ambitions-at-arcinova [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Arcinova has appointed a new Chief Scientific Officer to further accelerate the company's growth.

)

Senior appointment demonstrates growth ambitions at Arcinova

An experienced senior business leader, Dr Gareth Jenkins CChem FRSC has joined the Alnwick, UK based firm to support it in applying new technologies ...

Find Out More

stdClass Object ( [id] => 248 [title] => Arcinova secures £5 million BGF investment [alias] => arcinova-announces-major-increase-in-turnover [title_alias] => [introtext] =>

BGF has invested £5 million growth capital in Arcinova following a period of rapid growth and development at our site in Alnwick.

[language] => * [fulltext] =>

BGF has invested £5 million growth capital in Arcinova following a period of rapid growth and development at our site in Alnwick, Northumberland. We will use the funding to drive continued innovation as well as international expansion. 

Arcinova has been spearheading the use of new intensive manufacturing technology processes to support the rapid development of pioneering drugs for the treatment of life-threating illnesses including cancer. 

As a result of its innovative approach, Arcinova has more than doubled its customer base to 125 in the past two years, generating revenue of close to £9 million. 

Arcinova was founded in 2016 by serial entrepreneurs, Professor Ian Shott CBE (CEO), and Paul Ryan (CFO), after the acquisition of a 15,000m2 contract research facility in Alnwick, previously owned by Covance. 

Since then, our team has extended the facility’s capabilities into Active Pharmaceutical Ingredient (API) manufacture and has brought together a range of specialisms including drug substance synthesis, formulation and manufacture as well as bioanalytic, metabolism and radiolabelling services. Our facility is now one of the most technically advanced of its kind in the UK, with growing capacity to take on more work from both existing and new customers.

Professor Shott has been heavily involved in promoting clean and efficient chemistry and biotechnology processes to minimise the environmental impact of drug development and manufacture, and help pharmaceutical companies take potentially transformative new medicines through clinical development quickly and effectively. He is visiting Professor at Nottingham, Newcastle and Oxford Universities.

Arcinova is currently working on a major continuous technology project with Nottingham University, which has secured grant funding from Innovate UK. 

BGF, a £2.5 billion investment company, will provide support as a long-term minority shareholder in the business. The initial funding will be used for further investment in the joint-project, as well as new equipment, infrastructure and people in the UK and overseas to further increase capacity. 

Following an introduction by BGF, Arcinova has appointed Mike Hudson, co-founder of Neuropharm, as non-executive Chair. With broad industry experience, Mike will provide support and guidance to the Arcinova team as it implements its growth plans. 

This is the second company based in Alnwick to have received BGF’s backing, following its investment in family-owned housebuilder Cussins. BGF, which has made investments in over 220 growing companies across the UK, last month became the first and only investor to have been honoured for Innovation in the Queen’s Awards for Enterprise. 

Professor Ian Shott, CEO, Arcinova said: “This is an exciting time for Arcinova. We have a fantastic team, a world-class facility and strong market opportunity. We selected BGF because of their long-term approach to investing, and their ability to provide additional funding as we embark on a period of capital expenditure and international expansion.”

Barry Jackson, BGF, said: “Ian and Paul have the ambition and potential to build a modern, state-of-the-art business of significant scale. 

“Given the long-standing history of the Alnwick site, which has been reorganised to drive the new business model since the acquisition, it is great to see the team powering up the business, expanding its footprint and securing a strong order book. We’re delighted to be backing Arcinova as its new minority investor.” 

The deal was led for BGF by Barry Jackson, Rob Johnson and Mark Bryant.  

Arcinova were advised by Ben Butler and Anna McGill of Womble Bond Dickinson and BGF were advised by Duncan Reid and Kirsty Adamson of Watson Burton.

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-06-17 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-06-18 13:12:32 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-06-17 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/BGF news square.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/BGF news square.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 386 [xreference] => [featured] => 0 [readmore] => 3942 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-06-17 11:06:00 [slug] => 248:arcinova-announces-major-increase-in-turnover [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

BGF has invested £5 million growth capital in Arcinova following a period of rapid growth and development at our site in Alnwick.

)

Arcinova secures £5 million BGF investment

BGF has invested £5 million growth capital in Arcinova following a period of rapid growth and development at our site in Alnwick, Northumberland. We will ...

Find Out More

stdClass Object ( [id] => 286 [title] => Arcinova announces major increase in turnover [alias] => turnover-growth [title_alias] => [introtext] =>

Contract Research and Development Organisation Arcinova has announced a major growth in global sales.

[language] => * [fulltext] =>

The Alnwick, UK-based company – which provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies – has seen its sales increase by nearly 60 per cent from 2016 to 2017, from £5.3 million to £8.4 million. 

Arcinova provides drug substance synthesis, drug product manufacture, chemistry, manufacturing and controls (CMC), bioanalytical/metabolism, radiolabelled (active pharmaceutical ingredient and drug product) services and synthesis of toxic/highly potent active pharmaceutical ingredients (APIs). It also provides consultancy services and works in partnership with companies throughout the drug development process.

The company has attributed this growth to a major increase in client numbers, from 50 in February 2016 to more than 125 over 22 countries in less than 24 months. It has also pointed to an increase in the number of clients who are tapping into a broader range of Arcinova’s specialist services, which are all delivered from a single 15,000m2 facility on a 34-acre site.

Arcinova was launched in February 2016, following the acquisition of the Covance site in Alnwick, Northumberland, UK by Arc Trinova Limited, a new company formed by Ian Shott and Paul Ryan, owners of Shott Trinova LLP. 

The Arcinova site was formerly owned by Sanofi, before being bought by Covance in 2010. Its current team is a mix of leaders drawn from the legacy Covance organisation and new recruits.

The company has almost doubled its workforce in the last two years and has recently recruited new scientists into its Bioanalysis, API and CMC teams, as well as adding to its senior leadership team.

Arcinova has benefited from decades of investment as a key research and development centre for Sanofi and Covance, allowing it to offer a unique range of complementary on-site capabilities as a CRDO.

Arcinova this month announced the award of a £1.5 million Innovate UK grant for the development of new flexible modular manufacturing technologies, a project which is set to demonstrate the operating feasibility of world first innovative continuous production tools.

The project, which will span a three-year period, will be undertaken in collaboration with a team at the University of Nottingham. 

The company has also announced a new collaboration with Cramlington, Northumberland-based Sterling Pharma Solutions, a world leading provider of small molecule API development and manufacturing services to the global pharmaceutical industry. Arcinova now has access to Sterling Pharma Solutions’ scale up and pilot plant assets, which will complement the company’s existing facilities in Alnwick. 

Ian Shott, CEO of Arcinova, said: “This growth in sales is testimony to the world class science that is being delivered by our team and our ability to help companies bring life changing medicines to market more rapidly and cost effectively. 

“We are continuing to invest in our facilities, capabilities and workforce, which demonstrates our commitment to the pharmaceutical and biotech industries in the UK and across the world – and we’re looking forward to seeing further growth as we move forward.” 

Paul Ryan, Finance Director of Arcinova, added: “We have built on our relationships with existing customers, attracted new clients and have witnessed more and more companies tapping into the wider range of integrated services that we offer. 

“By providing a range of integrated specialist services on one site, Arcinova can offer a more efficient, cost effective service, helping customers to streamline the research and development process.

“In addition, although our Alnwick site – and many members of our scientific team – already have a long-established reputation in the global pharmaceutical and biotech communities, the name of Arcinova has now become established in its own right as a CRDO and this is having an impact on the continued growth of the business.”

Arcinova’s senior scientific team are renowned for their world class, specialist research and development expertise and their big pharma and CRDO experience gives them extensive, broad ranging industry knowledge and insight.

Arcinova works with big pharma, specialty pharma and biotech companies across the globe, from established multinationals to emerging start-ups.

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-05-10 13:17:00 [created_by] => 859 [created_by_alias] => [modified] => 2018-06-18 13:17:50 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-05-10 13:17:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/EBF SQuare.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/EBF SQuare.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 136 [xreference] => [featured] => 0 [readmore] => 4489 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Faye Coates [author_email] => Faye.Coates@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-05-10 13:17:00 [slug] => 286:turnover-growth [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Contract Research and Development Organisation Arcinova has announced a major growth in global sales.

)

Arcinova announces major increase in turnover

The Alnwick, UK-based company – which provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies – has seen its sales ...

Find Out More

stdClass Object ( [id] => 233 [title] => Arcinova hosts NEPIC Pharmaceutical Conference 2018 [alias] => arcinova-hosts-nepic-pharmaceutical-conference-2018 [title_alias] => [introtext] =>

Arcinova successfully hosts the NEPIC conference which discussed High Potency Processing. 

[language] => * [fulltext] =>

The challenges of high potency processing – and the innovations and solutions to help overcome them – were in the spotlight at The North East of England Process Industry Cluster (NEPIC) Pharmaceutical Conference 2018, which was held at our Alnwick site.

The conference, which took place on May 1, brought together an expert panel of speakers and industry professionals who provided insights into a number of aspects of high potency processing, including: categorisation; risk assessment; process development issues; creating a facility for HPAPI; manufacturers’ perspectives; and design and engineering issues.

NEPIC is a membership cluster organisation working with the chemical-using industries in the North East of England. It covers a broad sweep of chemistry-focussed industries including pharmaceuticals, biotechnology, petrochemicals, polymers and materials, fine and speciality chemicals and renewables. 

The day offered a variety of networking opportunities and a chance for delegates to build alliances in the pharmaceutical sector. 

Representatives of Arcinova, BPE, Fujifilm Diosynth Biotechnologies, Safebridge Consultants, YProTech, ProSys Sampling Systems, WH Partnership, Solo Containment, HPAPI Project Services and S3 Processing presented at the event. 

Paul Quigley, Head of API Development and Bioanalytical Services at Arcinova, presented on market drivers for highly potent Active Pharmaceutical Ingredients (APIs).This included pharma sales growth expectations in the next few years, and small molecule API trends and their role in driving pharmaceutical growth.

A panel discussion at the end of the session allowed speakers to share their knowledge and expertise on market trends, technical challenges and effective solutions. This was followed by a guided tour through our 15,000m2  facility. 

The conference was Philip Aldridge’s first event as the new CEO of NEPIC. He first joined the cluster in 2012 and specialised in supporting the pharmaceutical sector in the North East before taking up his new role as CEO.

Philip Aldridge, CEO of NEPIC, said: “I am delighted with the outcome of NEPIC’s pharmaceutical conference held at Arcinova’s Alnwick facility. We heard from a wide range of speakers covering the subject of high potency processing from a number of angles, which provided the large audience with a holistic view of an important pharmaceutical manufacturing trend. 

“The professional help we received from Arcinova staff and their excellent facilities contributed significantly to what was a very successful event. I was particularly pleased that a number of the world class speakers assembled said that this conference was better than most they had presented at recently covering this subject. 

“What NEPIC does best is to get business communities together to share best practice and make new business connections. I felt that this conference achieved this for a very important sector of the North East economy.”

Ian Shott, CEO of Arcinova, said: “At Arcinova, we understand the success of the North East pharmaceutical sector depends on regional organisations working together. We are very happy to have collaborated with NEPIC to help strengthen and promote the pharmaceutical sector in North East England and we were thrilled to welcome delegates to our site in Alnwick. As a business we are committed to helping the sector in the North East to grow and prosper.

“We saw specialists from the pharmaceutical sector sharing knowledge on high potency processing and bringing an outstanding level of technical expertise to the table, expertise that was shaped by real life experiences in industry. The panel discussion also opened up new debates and provided much food for thought around high potency processing and it is testimony to NEPIC’s strength as a cluster that delegates and speakers from across the UK attended the conference.”

The North East of England has a strong heritage in pharmaceutical manufacturing, capability and expertise. The region is home to over 1000 life science and healthcare companies that together employ 38,000 people, generate a combined turnover of £10.5 billion and contribute 33% of the UK’s pharmaceutical GDP.

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-05-10 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-05-14 13:21:17 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-05-10 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/nepic conf website sq.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/nepic conf website sq.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 269 [xreference] => [featured] => 0 [readmore] => 4365 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-05-10 11:06:00 [slug] => 233:arcinova-hosts-nepic-pharmaceutical-conference-2018 [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

Arcinova successfully hosts the NEPIC conference which discussed High Potency Processing. 

)

Arcinova hosts NEPIC Pharmaceutical Conference 2018

The challenges of high potency processing – and the innovations and solutions to help overcome them – were in the spotlight at The North East of ...

Find Out More

stdClass Object ( [id] => 234 [title] => Arcinova increases GC-MS/MS capabilities with new system [alias] => arcinova-increases-gc-ms-ms-capabilities-with-new-system [title_alias] => [introtext] =>

We have doubled bionanalysis capability by investing in another GC-MS/MS system. 

[language] => * [fulltext] =>

We have installed a new Thermo Scientific™ TSQ™ Duo triple quadrupole GC-MS/MS system at our Alnwick site. 

The addition of this new system has allowed us to double our capacity in GC-MS as well as expand our analytical capabilities.  

The system is tailored to chromatographers and single quadrupole GC-MS users who need easy access to powerful new workflows through MS/MS and the ability to meet their current method requirements.  

It features selected reaction monitoring (SRM) which cuts through heavy matrix backgrounds for clear detection of target compounds.

Its Thermo Scientific™ TRACE™ 1300 Series gas chromatograph is configurable for headspace and liquid injection and allows us to address a huge variety of GC and GC-MS applications. 

This system is also effective in enabling us to streamline our operations with one data system for GC, autosampler and MS. It features Tracefinder an intelligent functionality which supports increased efficiency in our laboratories. 

Our site is also fully equipped with Agilent GC-MS with EI/CI Source and GERSTEL multi-purpose sampler with liquid and headspace capacity, providing us with extra capability when working with small volatile molecules.

Stuart McDougall, Bioanalysis Leader at Arcinova, said: “We are continuing to invest in state-of-the-art equipment to match our world class capabilities and expertise, and the Thermo Scientific™ TSQ™ Duo triple quadrupole GC-MS/MS system will play a key part in the expansion of our GC-MS services. 

“It will allow us to offer more capacity to clients and we’re delighted to now have this system at our disposal.”

For more information on our GC-MS services, click here

[checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [catid] => 9 [created] => 2018-05-10 11:06:00 [created_by] => 858 [created_by_alias] => [modified] => 2018-05-15 09:23:08 [modified_by] => 859 [modified_by_name] => Faye Coates [publish_up] => 2018-05-10 11:02:00 [publish_down] => 0000-00-00 00:00:00 [images] => {"image_intro":"images\/GC-MS website SQuare.jpg","float_intro":"","image_intro_alt":"","image_intro_caption":"","image_fulltext":"images\/GC-MS website SQuare.jpg","float_fulltext":"","image_fulltext_alt":"","image_fulltext_caption":""} [urls] => {"urla":false,"urlatext":"","targeta":"","urlb":false,"urlbtext":"","targetb":"","urlc":false,"urlctext":"","targetc":""} [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [metadata] => {"robots":"","author":"","rights":"","xreference":""} [metakey] => [metadesc] => [access] => 1 [hits] => 270 [xreference] => [featured] => 0 [readmore] => 1964 [state] => 1 [category_title] => News [category_route] => news [category_access] => 1 [category_alias] => news [author] => Mark Chadwick [author_email] => mark.chadwick@arcinova.uk [contactid] => [parent_title] => ROOT [parent_id] => 1 [parent_route] => [parent_alias] => root [rating] => [rating_count] => [published] => 1 [parents_published] => 1 [alternative_readmore] => [layout] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 0 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 0 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 0 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 1 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => none [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 1 [show_category_title] => 0 [show_description] => 1 [show_description_image] => 0 [maxLevel] => 1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 0 [show_base_description] => 1 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 0 [num_intro_articles] => 9 [num_columns] => 3 [num_links] => 0 [multi_column_order] => 1 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => order [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [layout_type] => blog [menu_text] => 1 [page_title] => Latest News from Arcinova [show_page_heading] => 0 [pageclass_sfx] => news [menu-meta_description] => Find out the most recent news from the team at Arcinova. [secure] => 0 [page_description] => [page_rights] => [robots] => [access-view] => 1 ) ) [displayDate] => 2018-05-10 11:06:00 [slug] => 234:arcinova-increases-gc-ms-ms-capabilities-with-new-system [parent_slug] => [catslug] => 9:news [event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) [text] =>

We have doubled bionanalysis capability by investing in another GC-MS/MS system. 

)

Arcinova increases GC-MS/MS capabilities with new system

We have installed a new Thermo Scientific™ TSQ™ Duo triple quadrupole GC-MS/MS system at our Alnwick site. 

The addition of ...

Find Out More